There's no end in sight for the Indian pharmaceutical industry's struggles with domestic and foreign drug regulators. It's true that quite a few companies have received clean chits from regulators in the US, UK and Europe. However, at the same time, new issues have also been cropping up with disturbing frequency.
first published: Feb 23, 2017 10:00 pm
A collection of the most-viewed Moneycontrol videos.

Meesho's Rs 5,421 Cr IPO Kicks Off| Post-IPO Playbook, Profitability Path & More| IPO Watch Live

Can Nifty Hold Above 26,000 Amid Currency Jitters? Meesho IPO Opens | Opening Bell Live

Nifty Struggles Below 26,100 On Weekly F&O Expiry As Rupee Hits New Low| Closing Bell Live

Will Rupee Slide & Expiry Day Caution Keep Nifty Bulls On The Back Foot? | Opening Bell Live
You are already a Moneycontrol Pro user.

